Risk to bone health during treatment of endometriosis with dienogest
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
- Treatment for endometriosis with dienogest (DNG) associated with bone loss in 75%.
- Clinical significance is unclear.
Why this matters
- Endometriosis affects 10% of reproductive-aged women and is associated with pain and infertility.
- DNG is a synthetic nortestosterone derivative that selectively binds to progesterone receptors and causes anovulation.
- 75% of women experienced bone loss.
- Bone mineral density (BMD) at the lumbar spine decreased after the first 6 mo (−2.2%±4.5%; P=.001) and at 1 y (−2.7%±5.4%; P=.001).
- Differences in BMD were similar after 1 y and 2 y of treatment.
- Pain and endometriosis recurrence was reduced in women using DNG.
- Prospective cohort study.
- Cohort taken from the Endometriosis Cohort a...